Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Reexamination Certificate
2006-03-28
2006-03-28
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
C424S094100, C435S023000, C514S002600, C530S327000, C530S501000, C530S370000, C530S377000, C530S826000
Reexamination Certificate
active
07018633
ABSTRACT:
Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.
REFERENCES:
patent: 4293652 (1981-10-01), Cohen
patent: 4350626 (1982-09-01), Masuho et al.
patent: 4356270 (1982-10-01), Itakura
patent: 4416988 (1983-11-01), Rubin
patent: 4450154 (1984-05-01), Masuho et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4792447 (1988-12-01), Uhr et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4906469 (1990-03-01), Jansen et al.
patent: 4962188 (1990-10-01), Frankel
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5165923 (1992-11-01), Thorpe et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5591829 (1997-01-01), Matsushita
patent: 5622838 (1997-04-01), Lord et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5645836 (1997-07-01), Kitto
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5684024 (1997-11-01), Diana et al.
patent: 5767072 (1998-06-01), Vitetta et al.
patent: 5821243 (1998-10-01), Diana et al.
patent: 5830894 (1998-11-01), Pevear et al.
patent: 5834599 (1998-11-01), Chang et al.
patent: 5935957 (1999-08-01), Diana et al.
patent: 5981493 (1999-11-01), LaGrone
patent: 6333303 (2001-12-01), Borgford
patent: WO97/41233 (1997-11-01), None
Lord, J.M., et al, “Ricin: Structure, Mode of Action, and Some Current Applications”,The FASEB Journal, vol. 8 pp. 201and 206, Feb. 1994.
Richardson, P.T. et al, “Recombinant Proricin Binds Galactose But Does Not Depurinate 28 S Ribosomal RNA,”FEBS 07564, vol. 255, No. 1, p. 15, Sep. 1989.
Westby, M.W., et al, “Preparation and Characterization of Recombinant, Proricin Containing an Alternative Protease-Sensitive Linker Sequencer,”Bioconjugate Chemistry, 1992, 3, p. 375.
Darket, P.L., et al., “Human Immunodeficiencey Virus Protease,”Journal of Biological Chemistry, vol. 264, No. 4, p. 2307 1989.
Jordan, S.P., et al, “Activity and Dimerization of Human Immunodeficiency Virus Protease as a Function of Solvent Composition and Enzyme Concentration,”Journal of Biological Chemistry, vol. 267, No. 28, p. 20028. 1992.
Van Quen, M.G., “Rationals for the Use of Immunotixins in the Treatment of HIV-Infected Humans,”Journal of Drug Targeting, vol. 5, No. 2, p. 75, 1997.
Wachinger, M., et al, “Bryodin, a Single-Chaim Ribosome-Inactivating Protein, Selectively Inhibits the Grown of HIV-1-Infected Cells and Reduces HIV-1 Production,”Research in Experimental Medicine, 193:1-2, 1993.
Till, M.A., et al., “HIV-Infected Cells are Killed by rCF4-Ricin A Chain,”Science, vol. 24, p. 1166.
Alakhov, V.Y., et al., Increasing Cytostatic Effects of Ricin A Chain andStaphylococcus aureusEnterotoxin A Through In Vitro Hydrophobization with Fatty Acid Residues, 12 Biotechnol. Appl. Biochem. 94-98 (1990).
Brown, E.L., et al., 68 Meth. Enzymol. 109 (1979) (phosphodiester method).
Buller, R.M.L., et al., Poxvirus Pathogenesis, 55 Microbiol. Rev. 80-122 (1991).
Chou, K.C., A Vectorized Sequence-coupling Model for Predicting HIV Protease Cleavage Sites in Proteins, 268 J. Biol. Chem. 16938-16948 (1993).
Claverie, J.M., et al., T-immunogenic Peptides Are Constituted of Rare Sequences Patterns. Use in the Identification of T Epitopes in the Human Immunodeficiency Virus Gag Protein, 18 J. Eur. Immunol. 1547-1553 (1988).
Closs, O., et al., Stimulation of Human Lymphocytes by Galactose-specificAbrusandRicinusLectins, 115 J. Immunol. 1045-1048 (1975).
Finberg, R.W., et al., Selective elimination of HIV-1-infected Cells with an Interleukin-2 Receptor-specific Cytotoxin, 252 Science 1703-1705 (1991).
Frenoy, J.P., et al., Uptake of Injected1251-ricin by Rat Liver In Vivo, 284 Biochem. J. 249-257 (1992).
Gatlin, J., et al., Regulation of Intracellular Human Immunodeficiency Virus Type-1 Protease Activity, 244 Virology 87-96 (1998).
Ghiara, J.B., et al., Crystal Structure of the Principal Neutralization Site of HIV-1, 264 Science 82-85 (1994).
Halling, K.C., et al., Genomic Cloning and Characterization of a Ricin Gene from Ricinus communis, 13 Nucleic Acids Res. 8019-8033 (1985).
Hung, C.H., et al., Cloning and Expression of Three Abrin A-chains and Their Mutants Derived by Site-specific Mutagenesis inEscherichia coli, 219 Eur. J. Biochem. 83-87 (1994).
Hung, C.H., et al., Primary Structure of Three Distinct Isoabrins Determined by cDNA Sequencing: Conservation and Significance, 229 J. Mol. Biol. 263-267 (1993).
Hunkapiller et al., 310 Nature 105-111 (1984).
Kabanov, A. V., et al., Fatty Acylation of Proteins for Translocation Across Cell Membrane, 1 Biomed. Sci. 33-36 (1990).
Keener William K.
Ward Thomas E.
Battelle Energy Alliance, LLC
Stucker Jeffrey
Trask Britt P.C.
LandOfFree
Selective destruction of cells infected with human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective destruction of cells infected with human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective destruction of cells infected with human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3601994